Goldman LS, Genel M, Bezman RJ &, Slanetz PJ (1998): Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents
Doctors will get a closer look at how Lilly and Novo's pills compare in the coming months when Lilly releases the results of a head-to-head trial of the two, Lilly's Chief Scientific Officer Dan Skovronsky said in an exclusive interview with CNBC
In a lab environment where multiple compounds may be in circulation at once, an unlabeled vial isnt just inconvenient its a research validity risk, since theres no way to confirm identity or freshness after the fact
Amazing products, exceptional ingredients, no compromises.
This kind of rhythm prevents fatigue and keeps curiosity alive
Occluded superior Mesenteric Artery and Vein